#USA #Clinical Trials #Pleasanton #Veeva Study Builder #EDC System

Veeva Introduces the Study Builder Agent

In an exciting development for the clinical research sector, Veeva Systems (NYSE: VEEV) has unveiled its latest innovation, the Veeva Study Builder Agent, designed to streamline and enhance the configuration of clinical studies within a single day. The new solution leverages advanced artificial intelligence technology, allowing researchers to set up Veeva EDC (Electronic Data Capture) and Veeva DQS (Data Quality System) directly from a study protocol.

This breakthrough is especially significant as the agent utilizes an organization’s existing standards and is built upon the Unified Study Definitions Model (USDM) from the Clinical Data Interchange Standards Consortium (CDISC). This ensures that study setups not only happen rapidly but with a deterministic framework that significantly reduces discrepancies from established norms.

Key Functionalities of the Study Builder Agent

The Veeva Study Builder Agent is equipped with numerous capabilities:

• - Configuration of EDC Forms: Researchers can easily create data collection forms tailored to specific study needs within a day.
• - Visit and Validation Rules Setup: This includes the configuration of visits and the establishment of validation logic, vital for data integrity.
• - Automated Testing: The agent automates testing processes by generating test data, thereby facilitating a more efficient experimental process.
• - Compliance Ready: By adhering to pre-existing organizational standards in a coordinated manner, the solution offers outputs that are inherently audit-ready.

Drew Garty, the Chief Technology Officer at Veeva Clinical Data, emphasized the importance of this innovation: “The Veeva Study Builder Agent is set to significantly accelerate the design of high-quality studies. We are committed to implementing innovations that simplify, standardize, and connect clinical trials, and the Study Builder Agent is a monumental step towards realizing that vision.”

Availability and Future Prospects

The solution is expected to be available for initial users by December 2026, becoming an integral part of the EDC offering without the need for any additional licensing. It operates as a plugin within the Claude Cowork platform and is readily installable from a Veeva-managed GitHub repository.

Professionals in the life sciences sector can learn more about Veeva Clinical Data, including EDC, DQS, and eCOA, at the upcoming Veeva RD and Quality Summit scheduled for October 20-21 in Boston. This exclusive event will gather key industry stakeholders to discuss the latest advancements.

About Veeva Systems

Veeva Systems is a leading provider of cloud-based solutions tailored for the life sciences industry, offering a comprehensive suite of applications, data, and consulting services. With a client base of over 1,500 companies, including some of the largest biopharmaceutical firms and emerging biotech companies, Veeva is known for its commitment to fostering innovation and delivering exceptional product quality and client success. The organization aims to balance the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Forward-Looking Statements

This release contains forward-looking statements regarding Veeva’s products and services, as well as the expected outcomes or benefits from using our solutions. These statements are based on current expectations, and actual results may differ significantly. Various factors, as mentioned in our risk report on the Form 10-Q for the fiscal year ending July 31, 2026, could impact our results. Please refer to the SEC filings for additional risk details.

For further inquiries, contact:
Deivis Mercado
Veeva Systems
Phone: 925-226-8821
Email: [email protected]